Akemi Osawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akemi Osawa has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Lilian Yuri Itaya Yamaga
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
3 shared publications - Solange Amorim Nogueira
Hospital Israelita Albert Einstein, São Paulo, Brazil
3 shared publications - Adham Do Amaral e Castro
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications - Eduardo Kaiser Ururahy Nunes Fonseca
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications - Jorge Mejia
Einstein—Hospital Israelita, Sao Paulo 05652-900, Brazil
2 shared publications - Marycel Figols de Barboza
Hospital Israelita Albert Einstein, São Paulo 05652-900, Brazil
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Expanding the role of ivabradine in thyrotoxic crisis: a case report and Insights from the Literature
- 23 October 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Open AccessExpanding the role of ivabradine in thyrotoxic crisis: a case report and Insights from the Literature
- 27 January 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (8) , 1747-1758
Radioguided Occult Lesion Localization (ROLL) and Radioactive Seed Localization (RSL) versus Wire-guided Localization (WGL) in Breast-conserving Surgery for Non-Palpable Breast Cancer: a Systematic Review and Meta-analysis of Randomized Controlled Trials
- 27 January 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (8) , 1747-1758
Radioguided Occult Lesion Localization (ROLL) and Radioactive Seed Localization (RSL) versus Wire-guided Localization (WGL) in Breast-conserving Surgery for Non-Palpable Breast Cancer: a Systematic Review and Meta-analysis of Randomized Controlled Trials
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 58, e20250073
Real-life diagnostic performance of opportunistic computed tomography screening for osteoporosis in Brazilian adults: a retrospective validation study
Objective: To evaluate the diagnostic accuracy of computed tomography (CT) for detecting osteoporosis in Brazilian adults, using dual-energy X-ray absorptiometry (DXA) as the reference standard. Materials and Methods: We conducted a retrospective analysis of adults over 50 years of age who underwent CT (chest, abdominal, or lumbar scans) and DXA within a 60-day interval, between January 2012 and December 2022. Vertebral bone attenuation at L1 was quantified in Hounsfield units. Thresholds of > 160 HU and < 100 HU were used in order to classify bone as normal and osteoporotic, respectively. Two musculoskeletal radiologists, working independently, performed subjective classifications. Sensitivity, specificity, predictive values, and interobserver agreement (Cohen’s kappa) were calculated. The influence of contrast use and scanner heterogeneity was considered. Results: Ninety-five patients met the inclusion criteria. On the basis of the DXA results, we identified 39 normal cases, 46 cases of osteopenia, and 10 cases of osteoporosis. For detecting normal bone, objective CT measurements demonstrated a sensitivity of 88.6% and a specificity of 95.5%. For detecting osteoporosis, the sensitivity was 75.3% and the specificity was 99.7%. For the subjective classification, the level of interobserver agreement was fair (κappa = 0.384). The study included CT scans from different scanner models, with and without contrast enhancement. Conclusion: Opportunistic CT demonstrated high specificity but only moderate sensitivity for osteoporosis detection. The attenuation thresholds previously validated in populations elsewhere show promise for use in Brazil. However, scanner variability, contrast use, and limited sample size constrain generalizability. Larger, multicenter prospective studies are warranted.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 58, e20250073
Open AccessReal-life diagnostic performance of opportunistic computed tomography screening for osteoporosis in Brazilian adults: a retrospective validation study
Objective: To evaluate the diagnostic accuracy of computed tomography (CT) for detecting osteoporosis in Brazilian adults, using dual-energy X-ray absorptiometry (DXA) as the reference standard. Materials and Methods: We conducted a retrospective analysis of adults over 50 years of age who underwent CT (chest, abdominal, or lumbar scans) and DXA within a 60-day interval, between January 2012 and December 2022. Vertebral bone attenuation at L1 was quantified in Hounsfield units. Thresholds of > 160 HU and < 100 HU were used in order to classify bone as normal and osteoporotic, respectively. Two musculoskeletal radiologists, working independently, performed subjective classifications. Sensitivity, specificity, predictive values, and interobserver agreement (Cohen’s kappa) were calculated. The influence of contrast use and scanner heterogeneity was considered. Results: Ninety-five patients met the inclusion criteria. On the basis of the DXA results, we identified 39 normal cases, 46 cases of osteopenia, and 10 cases of osteoporosis. For detecting normal bone, objective CT measurements demonstrated a sensitivity of 88.6% and a specificity of 95.5%. For detecting osteoporosis, the sensitivity was 75.3% and the specificity was 99.7%. For the subjective classification, the level of interobserver agreement was fair (κappa = 0.384). The study included CT scans from different scanner models, with and without contrast enhancement. Conclusion: Opportunistic CT demonstrated high specificity but only moderate sensitivity for osteoporosis detection. The attenuation thresholds previously validated in populations elsewhere show promise for use in Brazil. However, scanner variability, contrast use, and limited sample size constrain generalizability. Larger, multicenter prospective studies are warranted.
- Open Access
- 28 December 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (1) , 48
Radiosynthesis Standardization and Preclinical Assessment of the [68Ga]Ga-DOTA-Ubiquicidin29-41: A Translational Study Targeting Differential Diagnosis of Infectious Processes
Human bacterial infections significantly contribute to the increase in healthcare-related burdens. This scenario drives the study of novel techniques for the early and precise diagnosis of infectious processes. Some alternatives include Nuclear Medicine- and Molecular Imaging-based strategies. However, radiopharmaceuticals that are available for routine assessments are not specific to differentiating infectious from aseptic inflammatory processes. In this context, [68Ga]Ga-DOTA-Ubiquicidin29-41 was synthesized using an automated module and radiochemical; in vivo and in vitro studies were performed. The radiopharmaceutical remained stable in saline (up to 180 min) and in rodent serum (up to 120 min) with radiochemical purities > 99 and 95%, respectively. Partition coefficient and serum protein binding at 60 min were determined (−3.63 ± 0.17 and 44.06 ± 1.88%, respectively). Ex vivo biodistribution, as well as in vivo microPET/CT images in mice, showed rapid blood clearance with renal excretion and reduced uptake in other organs in Staphylococcus aureus-infected animals. Higher uptake was observed in the target as compared to the non-target tissue (p < 0.0001) at 60 min post administration. The presented in-human clinical case demonstrates uptake of the radiopharmaceutical by Staphyloccocus aureus bacteria. These results indicate the potential of [68Ga]Ga-DOTA-Ubiquicidin29-41 as a radiopharmaceutical that can be obtained in a hospital radiopharmacy for the diagnosis of infectious processes using PET/CT.
- 28 December 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (1) , 48
Open AccessRadiosynthesis Standardization and Preclinical Assessment of the [68Ga]Ga-DOTA-Ubiquicidin29-41: A Translational Study Targeting Differential Diagnosis of Infectious Processes
Human bacterial infections significantly contribute to the increase in healthcare-related burdens. This scenario drives the study of novel techniques for the early and precise diagnosis of infectious processes. Some alternatives include Nuclear Medicine- and Molecular Imaging-based strategies. However, radiopharmaceuticals that are available for routine assessments are not specific to differentiating infectious from aseptic inflammatory processes. In this context, [68Ga]Ga-DOTA-Ubiquicidin29-41 was synthesized using an automated module and radiochemical; in vivo and in vitro studies were performed. The radiopharmaceutical remained stable in saline (up to 180 min) and in rodent serum (up to 120 min) with radiochemical purities > 99 and 95%, respectively. Partition coefficient and serum protein binding at 60 min were determined (−3.63 ± 0.17 and 44.06 ± 1.88%, respectively). Ex vivo biodistribution, as well as in vivo microPET/CT images in mice, showed rapid blood clearance with renal excretion and reduced uptake in other organs in Staphylococcus aureus-infected animals. Higher uptake was observed in the target as compared to the non-target tissue (p < 0.0001) at 60 min post administration. The presented in-human clinical case demonstrates uptake of the radiopharmaceutical by Staphyloccocus aureus bacteria. These results indicate the potential of [68Ga]Ga-DOTA-Ubiquicidin29-41 as a radiopharmaceutical that can be obtained in a hospital radiopharmacy for the diagnosis of infectious processes using PET/CT.
- Open Access
- 23 November 2023
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 21, eRC0621
Antimicrobial peptide for bacterial infection imaging: first case reported in Brazil
Molecular imaging markers can be used to differentiate between infection and aseptic inflammation, determine the severity of infection, and monitor treatment responses. One of these markers is ubiquicidin(29-41) (UBI), a cationic peptide fragment that binds to the bacterial membrane wall and is labeled with gallium-68 (68Ga), a positron emitter radioisotope. The use of UBI in positron emission tomography (PET)/computed tomography (CT) for improved detection of lesions has been receiving considerable attention recently. Herein, we report the first case of
- 23 November 2023
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 21, eRC0621
Open AccessAntimicrobial peptide for bacterial infection imaging: first case reported in Brazil
Molecular imaging markers can be used to differentiate between infection and aseptic inflammation, determine the severity of infection, and monitor treatment responses. One of these markers is ubiquicidin(29-41) (UBI), a cationic peptide fragment that binds to the bacterial membrane wall and is labeled with gallium-68 (68Ga), a positron emitter radioisotope. The use of UBI in positron emission tomography (PET)/computed tomography (CT) for improved detection of lesions has been receiving considerable attention recently. Herein, we report the first case of
- Open Access
- 20 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4209
Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is considerably more frequent in squamous cell lung cancer (SqCLC) than in other subtypes of lung cancer and may be a promising target for this histology. Here, we present the course of diagnosis and treatment of a patient with advanced SqCLC, harboring not only CDKN2A mutation but also PIK3CA amplification, Tumor Mutational Burden-High (>10 mutations/megabase), and a Tumor Proportion Score of 80%. After disease progression on multiple lines of chemotherapy and immunotherapy, he responded favorably to treatment with the CDK4/6i Abemaciclib and later achieved a durable partial response to immunotherapy rechallenge with a combination of anti-PD-1 and anti-CTLA-4, nivolumab, and ipilimumab.
- 20 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4209
Open AccessResponse to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is considerably more frequent in squamous cell lung cancer (SqCLC) than in other subtypes of lung cancer and may be a promising target for this histology. Here, we present the course of diagnosis and treatment of a patient with advanced SqCLC, harboring not only CDKN2A mutation but also PIK3CA amplification, Tumor Mutational Burden-High (>10 mutations/megabase), and a Tumor Proportion Score of 80%. After disease progression on multiple lines of chemotherapy and immunotherapy, he responded favorably to treatment with the CDK4/6i Abemaciclib and later achieved a durable partial response to immunotherapy rechallenge with a combination of anti-PD-1 and anti-CTLA-4, nivolumab, and ipilimumab.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 56 (4) , 220-225
Musculoskeletal pitfalls in 68Ga-PSMA PET/CT
Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed in normal prostate cells and overexpressed in prostate cancer. Consequently, it is an important tool in the evaluation of prostate cancer, including the staging of high-risk patients and the assessment of biochemical recurrence. Despite the “specific” designation, benign musculoskeletal conditions, such as fractures, osteodegenerative changes, and fibrous dysplasia, can also show PSMA uptake, which can lead to misinterpretation of the imaging findings. Therefore, radiologists must be aware of these potential pitfalls, understand their causes, and fully analyze their morphologic features on unfused computed tomography (CT) and magnetic resonance imaging scans to correctly interpret the examination. In this pictorial essay, we review the basic characteristics of the 68Ga-PSMA positron-emission tomography/CT (PET/CT) radiotracer, discuss potential causes of false-positive findings on 68Ga-PSMA PET/CT in the musculoskeletal system, and illustrate the corresponding imaging findings.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 56 (4) , 220-225
Open AccessMusculoskeletal pitfalls in 68Ga-PSMA PET/CT
Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed in normal prostate cells and overexpressed in prostate cancer. Consequently, it is an important tool in the evaluation of prostate cancer, including the staging of high-risk patients and the assessment of biochemical recurrence. Despite the “specific” designation, benign musculoskeletal conditions, such as fractures, osteodegenerative changes, and fibrous dysplasia, can also show PSMA uptake, which can lead to misinterpretation of the imaging findings. Therefore, radiologists must be aware of these potential pitfalls, understand their causes, and fully analyze their morphologic features on unfused computed tomography (CT) and magnetic resonance imaging scans to correctly interpret the examination. In this pictorial essay, we review the basic characteristics of the 68Ga-PSMA positron-emission tomography/CT (PET/CT) radiotracer, discuss potential causes of false-positive findings on 68Ga-PSMA PET/CT in the musculoskeletal system, and illustrate the corresponding imaging findings.
- Open Access
- 29 February 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 1-10
Is PET–CT an accurate method for the differential diagnosis between chondroma and chondrosarcoma?
The differential diagnosis between chondroma and intraosseous chondrosarcoma is based on imaging and clinical exams, but only a biopsy can confirm diagnosis. The aim of this study was to evaluate the value of PET–CT in differentially diagnosing chondroma and chondrosarcoma. From October 2009 to May 2015, 36 patients with cartilaginous bone lesions in the extremities, 12 (33.3 %) men and 24 (66.6 %) women, were prospectively included in the study. Patients ranged in age from 21 to 68 years, with a mean age of 44 years. Lesions were located in the long bones: in the proximal humerus in 26 (72.2 %) patients, in the femoral shaft in 1 (2.7 %), in the distal femur in 7 (19.4 %), and in the proximal tibia in 2 (5.5 %). The SUVmax value of 2.0 was used to separate between patients submitted to surgery and patients submitted to observation. Among the 36 patients studied, 17 (47.2 %) had SUVmax ≤ 2.0, and they were diagnosed as chondroma and they were treated conservatively. Follow-up ranged from 14 to 76 months, averaging 38 months. Nineteen (52.7 %) patients with SUVmax >2.0 were diagnosed as chondrosarcoma and underwent surgery. The area of the curve, calculated considering the SUV variable as numeric, is estimated in 0.966, with a 95 % confidence interval from 0.906 to 1.000. To evaluate the sensitivity, specificity and positive/negative predictive values, it was built a 2 × 2 table. Significance was set at p < 0.05. According the criteria of maximum sensitivity and specificity, the cut point suggested to SUVmax was 2.2. If we consider this point, it is possible to identify 19 of 36 positive cases to chondroma (52.8 %), it means, all chondrosarcomas of the series. We concluded that PET–CT can be used as an objective and quantitative method of differentiating between chondromas and chondrosarcomas located within the long bones. It represents a complementary examination to standard imaging (X-ray, scintigraphy, CT and MRI) and pathological exams. The SUVmax between 2.0 and 2.2 would be a range area between chondroma and chondrosarcoma and this range can be of value, among others exams, in decide the best treatment for patients with cartilaginous lesions in long bones. Level of evidence Level I—diagnostic study—prospectively investigating a diagnostic test using a universally applied “gold” standard.
- 29 February 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 1-10
Open AccessIs PET–CT an accurate method for the differential diagnosis between chondroma and chondrosarcoma?
The differential diagnosis between chondroma and intraosseous chondrosarcoma is based on imaging and clinical exams, but only a biopsy can confirm diagnosis. The aim of this study was to evaluate the value of PET–CT in differentially diagnosing chondroma and chondrosarcoma. From October 2009 to May 2015, 36 patients with cartilaginous bone lesions in the extremities, 12 (33.3 %) men and 24 (66.6 %) women, were prospectively included in the study. Patients ranged in age from 21 to 68 years, with a mean age of 44 years. Lesions were located in the long bones: in the proximal humerus in 26 (72.2 %) patients, in the femoral shaft in 1 (2.7 %), in the distal femur in 7 (19.4 %), and in the proximal tibia in 2 (5.5 %). The SUVmax value of 2.0 was used to separate between patients submitted to surgery and patients submitted to observation. Among the 36 patients studied, 17 (47.2 %) had SUVmax ≤ 2.0, and they were diagnosed as chondroma and they were treated conservatively. Follow-up ranged from 14 to 76 months, averaging 38 months. Nineteen (52.7 %) patients with SUVmax >2.0 were diagnosed as chondrosarcoma and underwent surgery. The area of the curve, calculated considering the SUV variable as numeric, is estimated in 0.966, with a 95 % confidence interval from 0.906 to 1.000. To evaluate the sensitivity, specificity and positive/negative predictive values, it was built a 2 × 2 table. Significance was set at p < 0.05. According the criteria of maximum sensitivity and specificity, the cut point suggested to SUVmax was 2.2. If we consider this point, it is possible to identify 19 of 36 positive cases to chondroma (52.8 %), it means, all chondrosarcomas of the series. We concluded that PET–CT can be used as an objective and quantitative method of differentiating between chondromas and chondrosarcomas located within the long bones. It represents a complementary examination to standard imaging (X-ray, scintigraphy, CT and MRI) and pathological exams. The SUVmax between 2.0 and 2.2 would be a range area between chondroma and chondrosarcoma and this range can be of value, among others exams, in decide the best treatment for patients with cartilaginous lesions in long bones. Level of evidence Level I—diagnostic study—prospectively investigating a diagnostic test using a universally applied “gold” standard.
- 1 June 2010
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 35 (6) , 452-453
F-18 FDG PET/CT Imaging in Small Cell Prostate Cancer
- 1 June 2010
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 35 (6) , 452-453
F-18 FDG PET/CT Imaging in Small Cell Prostate Cancer